Kornimate/medical-research-clean huggingface dataset:
the pilot study on tailored eradication therapy according to clarithromycin resistance in h.pylori patients

Conditions: Peptic Ulcer

Summary: this study assessed the effect of tailored eradication therapy according to clarithromycin resistance in helicobacter pylori patients.

this study assessed the effect of tailored eradication therapy according to clarithromycin resistance in helicobacter pylori patients. the patients with gastric or duodenal ulcer by endoscopy were registered at the study and inspected rapid urease test, biopsy, igg-hp antibody. the tailored eradication therapy was prescribed to patients that confirmed helicobacter pylori positive in two or more of among the three tests for 14 days. through this, this study is to assess the effectiveness of eradication rate and to evaluate safety and tolerability of ilaprazole 10mg qid treatment

Eligibility criteria:
inclusion criteria: * • 20 year old ≤ male or female \< 80 year old * among patients with gastric or duodenal ulcer by endoscopy, subject who is identified helicobacter pylori-positive in the conduct of two or more of the following tests ; rapid urease test, biopsy test, igg-hp antibody test. * subject who fully understands conditions of clinical trial * subject who agrees to participate and spontaneously sign the icf exclusion criteria: * known hypersensitivity to experimental and concomitant drugs * subjects who are taking contraindicated medications for experimental and concomitant drug. * subjects with abnormal levels in the laboratory tests * total bilirubin, creatinine\> 1.5 times upper limit of normal * ast, alt, alkaline phosphatase, bun\> 2 times upper limit of normal * administrated of ppi, antibiotic medication within 2 weeks prior to commencement of the study. * pregnant and/or lactating women * reproductive aged women not using contraception * uncontrolled diabetics * uncontrolled hypertension * uncontrolled liver dysfunction * alcoholics * subjects with a history or possibility of digestive malignancy within 5 years * subjects with a history of gastrectomy or esophagectomy * subjects with hereditary diseases such as galactose intolerance, lapp lactose deficiency, glucose-galactose malabsorption * subjects participating in a clinical trial before another trial within 30 days * inconsistence judged subject by researcher
efficacy and safety of olokizumab with rheumatoid arthritis with previously failed to anti-tumor necrosis factor (anti-tnf) therapy

Conditions: Rheumatoid Arthritis

Summary: the primary objective of this study is to evaluate the efficacy and safety of cdp6038 administered subcutaneous (sc) at various doses compared to placebo.


Eligibility criteria:
inclusion criteria: * have a diagnosis of adult-onset ra of at least 6 months' (24 weeks) duration as defined by the 1987 acr classification criteria or a score of ≥6 as defined by the acr/european league against rheumatism classification and diagnostic criteria for ra * must have moderately to severely active ra disease as defined by ≥6 tender joints (68-joint count) at screening and baseline, ≥6 swollen joints (66-joint count) at screening and baseline, crp ≥1.2 times the upper limit of normal (uln) or esr \>28mm/hour * must be on an mtx dose of 6 to 16mg/week in japan or 7.5 to 20mg/week in korea and taiwan, which has been stable for at least 6 weeks prior to screening with a stable route of administration * must have had intolerance or inadequate response to treatment with 1 or more tnf-blocker therapies within 2 years of screening * female subjects must be either postmenopausal for at least 1 year, surgically incapable of childbearing, or effectively practicing 2 acceptable methods of contraception exclusion criteria: * have a diagnosis of any other inflammatory arthritis * female subjects who are breast-feeding, pregnant, or plan to become pregnant during the study or within 24 weeks * disease modifying antirheumatic drug (dmards) other than methotrexate (mtx) * subjects with known concurrent acute or chronic viral hepatitis b or c infection * subject has known tuberculosis (tb) disease, high risk of acquiring tb infection, or latent tb infection * subjects with known history of or current clinically active infection * subjects at high risk of infection * subjects with known human immunodeficiency virus (hiv) or human t cell lymphotropic virus type 1 (htlv 1) infection * have received vaccinations within 8 weeks prior to screening or plan to receive vaccines during the study (with the exception of injectable influenza and pneumococcal vaccinations which are permitted) * concurrent malignancy or a history of malignancy (with the exception of successfully treated carcinoma of the cervix more than 5 years prior to screening or no more than 2 successfully treated basal cell carcinomas within 2 years prior to screening

Keywords: rheumatoid arthritis monoclonal antibody interleukin-6 olokizumab cdp6038
bion occipital nerve stimulation (ons) compassionate use study

Conditions: Chronic, Medically Refractory Headache

Summary: the purpose of this compassionate use study is to provide clinical and technical support of the bion® microstimulator system to the subjects who have decided to keep the system for relief of headache symptoms that have not responded to medical treatment. these study subjects were enrolled and implanted with the bion® system during a previous clinical investigation of the bion® for occipital nerve stimulation (ons) in the united states.


Eligibility criteria:
inclusion criteria: * subject participated in a prior clinical feasibility study of the bion for occipital nerve stimulation in the treatment of chronic headaches (ide g030225) and remained implanted with the bion system. * subject elects to enroll in this compassionate use study and provides written informed consent. * subject understands the type and duration of clinical, technical or product support provided in the study. * subject is willing to comply with protocol-required activities. exclusion criteria: * subject is currently participating or intends to participate in another investigational drug or device clinical trial for chronic headaches during the study period.
epidemiology of tnbc in asyut clinical oncology department

Conditions: Breast Cancer

Summary: epidemiological study about behavior of tnbc in clinical oncology department in 8 y in asyut university hospital

breast cancer )bc) is the most common malignancy in women in 2020, there were 2.3 million women diagnosed with breast cancer and 685.000 deaths globally. breast cancer rates are 88% higher in developed countries compared to developing countries . tnbc represents accounts for approximately 24% of all breast cancer in 2020 .while in egypt it accounts for 11.05% according to egyptian national bc (5). by gene expression profiling ,4 subtypes of tnbc emerged : luminal androgen receptor (lar), mesenchymal stem-like (msl), immunomodulatory (im), basal-like (bl1 and bl2) . most of cases are advanced with median survival about 14 months . brain and visceral organs represent common sites of distant metastasis . so it is considered the worst prognosis . in addition , chemotherapy is only option in treatment with no available targeted options for decades. now we have immunotherapy (io ) and parp inhibitors in neoadjuvant (nat) and metastatic setting for example : key note 355 which add pembrolizumab in nat which lead to marked improvement in pathological complete response ( pcr ) and in high risk patient and have marked results in disease and event free survival(8) .poly (adp-ribase) poly merase -1 (parp-1) inhibitors appear to particularly effective in brca 1/2 mutation carries (9) .as reviewed by rodleret al. emerging data suggest that brca 1/2 carriers with tnbc disease may respond favorably to cisplatin therapy .

Eligibility criteria:
inclusion criteria:- age ≥ 18 * male or female * diagnosed as tnbc from ( 2015- 2022 ) confirmed by pathology * adjuvant or metastatic exclusion criteria:- have other type of malignancy * her2 , er, pr positive
mannitol administration for delerium prevention

Conditions: Myocardial Infarction (MI); Delirium, Intensive Care Unit, Randomised Controlled Trial

Summary: the aim of the study is to evaluate the efficacy of adjuvant administration of mannitol for the prevention of delirium in patients with myocardial infarction.

the pathogenesis of delirium in patients with myocardial infarction has not been fully studied, as a result of which delirium is currently considered a polyetiological syndrome. the ideas about the pathogenesis of delirium are formulated in a number of concepts, among which the neuroinflammatory theory is the most promising for study. the development of a systemic inflammatory reaction of both infectious and aseptic nature can lead to a violation of the permeability of the blood-brain barrier, followed by subclinical cerebral edema and impaired neurotransmitter metabolism. a single study of the adjuvant use of mannitol for the prevention of delirium, conducted in 2020 (hamiko m.) proved the effectiveness of mannitol in the prevention of delirium in patients who underwent surgical aortic valve replacement, and served as a theoretical and experimental prerequisite for this study. the study is prospective, randomized, open-label, controlled. it is planned to include 40 patients with myocardial infarction aged 65 years or older on the first day of the disease ("pain-door" \ 25 mg / l) in the main and control groups in a 1: 1 ratio. all patients will receive standard treatment for myocardial infarction upon admission in accordance with current recommendations. patients will be randomized using a random number generator, after which patients in the main group will receive adjuvant therapy with mannitol at a dose of 1000 mg / kg according to the following scheme: bolus 250 mg / kg + infusion 66.6 mg / kg / hour until a total dose of 1000 mg / kg is reached. patients in the control group will receive standard treatment for myocardial infarction. it is planned to evaluate clinical, laboratory, functional data and take blood samples for the study of markers of systemic inflammation and brain damage and other biomarkers on days 1, 3 and 7. evaluation of remote outcomes is planned on days 30 and 90.

Eligibility criteria:
inclusion criteria: * age 65 and over * myocardial infarction in the first day of illness ("pain to door" time \< 254 hours) * serum crp \> 25 mg/l exclusion criteria: * a known pathological process in the brain, psychiatric disorders * impossibility of conducting an assessment cam-icu

Keywords: myocardial infarction delirium prevention inflammation
comparative effects of oscillatory mobilizations and mckenzie retraction exercises on mechanical neck pain

Conditions: Mechanical Neck Pain

Summary: the neck pain is a public health problem and a common source of disability in the general population. its exact pathology remains obscure, but the source of symptoms has been asserted to involve mechanical dysfunction of the cervical spine, particularly the zygoapophysial joints. among the diversity of neck pain, mechanical neck pain is the most common type, with the pain primarily confined in the area on the posterior aspect of the neck that can be exacerbated by neck movements or by sustained neck postures. the usual clinical presentation of this mechanical neck pain is a reduction in mobility of either a single segment or multiple segments of the cervical spine in association with pain. this study will be a randomized control trial and will be conducted at arif memorial teaching hospital lahore. the study will be completed within the time duration of six months. convenience sampling technique will be used to collect data. a sample size of 30 patients(15 in each group) which will fulfill inclusion criteria will be taken in the study. participants will be divided into two groups. both groups will be given conventional physical therapy and postural correction education. group a will be provide oscillatory mobilizations. the following grades will be use: grades i and ii for pain and grades iii and iv to increase joint range of motion. this oscillatory mobilization will perform at a rate of 2-3 oscillations per second. and a frequency of 3-4 mobilization of the joint lasting approximately 30 sec each. the rest time between each mobilization will be one minute for 5 days a week for four weeks , while group b will be treat withmckenzie retraction exercises in which foursets of 10-15 repetitions with 1-2 minutes rest between each set for 5 days a week during four weeks. data will collect by using tools like numeric pain rating scale to measure pain, universal goniometer will be use for range of motion and disability level will be record pre and post treatment by using neck disability index. then data will analyzed by using spss.


Eligibility criteria:
inclusion criteria: patient with primary complaint of non specific neck pain. pain of sufficient intensity (greater than 2 out of 10 on numerical pain scale) · pain and stiffness for at least 2 weeks pain aggravated by neck movement · exclusion criteria: history of orthopedic surgery to the neck and shoulder and temporo-mandibular joint neurological symptoms due to cervical dysfunction history of carcinoma progressive neurological deficits

Keywords: cervical spine exercise therapy pain manual therapy
efficacy/safety of lansoprazole in patients with frequent nighttime heartburn

Conditions: Frequent Heartburn

Summary: heartburn, a burning sensation in the chest or throat, occurs in many individuals when acidic stomach contents move upward into the esophagus from the stomach. this study will investigate the safety and efficacy of lansoprazole 15 mg or 30 mg administered once a day in preventing frequent nighttime heartburn.


Eligibility criteria:
inclusion criteria: * experiencing heartburn at least 2 days per week during the nighttime period over the past month. * having heartburn that responds to heartburn medication. * be willing to discontinue the use of heartburn treatment for 7 days prior to inclusion in the study. exclusion criteria: * having history of erosive esophagitis or gastroesophageal reflux disease diagnosed by a physician and confirmed by testing (endoscopy). * be unwilling to take only the study medication, and antacid provided as a rescue medication for relief of acute heartburn during the study. "other protocol-defined inclusion/exclusion criteria may apply"

Keywords: frequent heartburn, proton pump inhibitor, lansoprazole treatment of over 14 days
resistance exercise to improve flu vaccine for older adults

Conditions: Influenza, Human

Summary: this study evaluates whether resistance exercise will improve immune responses to the seasonal influenza vaccine in older adults. one third of the participants will perform exercise in the arm that receives the vaccine, one third of the participants will perform the same exercise in the arm that does not receive the vaccine, and one third will only receive the vaccine.

resistance exercise, particularly novel eccentric exercise, recruits immune cells to the targeted muscle. the exercises selected here targets the deltoid and biceps brachii muscles-those same muscles that the flu vaccine is delivered to during typical vaccination.

Eligibility criteria:
inclusion criteria: * non-frail older adult (≥65 years old) of any sex and race/ethnicity * non-smokers (\>10 yrs) * meets american college of sports medicine criteria for participation in exercise * us resident exclusion criteria: * underlying medical problems that contraindicate supervised resistance exercise * past or present history of autoimmune disease, hiv, hepatitis, stroke, or cardiovascular disease * current debilitating arthritis of the shoulder * central or peripheral nervous disorders * bedridden in the past three months * history of vaccine-related allergies, or severe egg allergy; * physician-confirmed influenza infection in the prior year * regular user of corticosteroids * functional or cognitive impairment that would limit exercise performance or prohibit informed consent * blood pressure greater than 160/90 * participation in resistance arm exercises in the prior 6 months

Keywords: exercise vaccine older adults
development of a device for evaluating primary hemostasis under whole blood flow conditions

Conditions: Von Willebrand Diseases; Major Constitutional Thrombopathy; Patient on Antiplatelet Drugs

Summary: currently, the exploration of primary hemostasis (a physiological phenomenon used to stop bleeding) is imperfect because it is based on targeted tests for platelets or von willebrand factor, without taking into account blood flow and other blood cells (red and white blood cells). tests for whole blood and flow conditions exist, but there is currently no test that comes close to actual physiological conditions. an exploration of whole blood haemostasis in a device that is similar to a blood vessel and at different flow conditions (venous and arterial) could help to better identify the risk of bleeding in predisposed patients (von willebrand factor deficiency, antiplatelet therapy). the objective of the study is to evaluate the performance of this new hemostasis test in whole blood and under flow conditions. participation in the study is ad hoc and is limited to adding a maximum of 4 citrated tubes (20 ml or the equivalent of 4 teaspoons) and 1 edta tube (5ml) to a routine blood sample (for patients) or during blood donation (for controls).


Eligibility criteria:
inclusion criteria: * person who has given oral consent * adult * blood donor at efs bourgogne franche-comté * or patient with von willebrand disease or major constitutional thrombopathy followed by the resource and competence centre (crc) - constitutional hemorrhagic diseases of dijon or besançon * or patient on antiplatelet drugs consulting for thrombosis at the dijon bourgogne or besançon hospital exclusion criteria: * a person who is not affiliated to or not a beneficiary of national health insurance * person subject to court-ordered protection (curatorship, guardianship) * pregnant, parturient or breastfeeding woman * a person who is unable to consent * person on anti-inflammatory treatment and serotonin reuptake inhibitor antidepressants (platelet function disorders)
to assess the level of adherence of subjects receiving saizen® via easypod™ in sweden

Conditions: Growth Disorders

Summary: this is a swedish, multicentre, observational registry to study adherence and long term outcomes of therapy in paediatric subjects using easypod™ electromechanical device for growth hormone treatment to assess the level of adherence of subject receiving saizen® via easypod™.

subjects will be enrolled in a multicenter longitudinal observational registry. parents/subjects will provide their informed consent/assent to upload their data for population-based analyses and optionally to adhere to a patient adherence support program designed to improve their adherence and, ultimately, clinical outcomes. adherence data will be primarily derived from the easypod™ device combined with physician data entry of outcome measures. data will be collected retrospectively and prospectively. this will allow the establishment of adherence profiles and explore the hypothesis that patient adherence support programs improve adherence and subsequent clinical outcomes. collected data will be also analyzed in a multinational pooled analysis of comparable national studies. primary objective: • to assess the level of adherence of subjects receiving saizen® via easypod™ secondary objectives: * to describe the impact of adherence on clinical outcomes for subject receiving saizen® via easypod™ * to identify adherence subject profiling based on age, gender, self injection or not, time on treatment, medical history at time of enrollment * to assess the impact of adherence on insulin-like growth factor 1 (igf1) (i.e. above, below or within normal ranges) other objectives: • to assess the impact of adherence on average blood glucose (hba1c)

Eligibility criteria:
inclusion criteria: * administered growth hormone via the easypodtm electromechanical device according to summary of product characteristics (smpc) * over the age of \> 2 years old * under \< 18 years of age, or over 18 years of age without fusion of growth plates * parent's or guardian's written informed consent, given before entering data into the registry , with the understanding that the subject or parent/guardian may withdraw consent at any time without prejudice to future medical care. if the child is old enough to read and write, a separate assent form will be given as defined in the appropriate jurisdiction of each country. exclusion criteria: * subjects taking growth hormone in whom growth plates have fused (i.e. for taking growth hormone for it's metabolic effects) * contra-indications to saizen® as defined in the smpc * use of an investigational drug or participation in an interventional clinical study

Keywords: growth disorders saizen easypod growth hormone pediatric subject
optimizing the impact of the healthy school recognized campus program on youth's cvd risk factors

Conditions: Cardiovascular Diseases; Physical Activity; Nutrition

Summary: healthy school recognized campus is a texas a\&m agrilife extension initiative that supports the delivery of school-based physical activity and nutrition programs for diverse youth across texas. the purpose of this study is to improve the delivery of these programs and optimize the effect they have on youth's cardiovascular risk factors.

the investigators will conduct a group randomized factorial trial using the multiphase optimization strategy (most) framework to evaluate the impact (i.e., implementation and effectiveness) of three implementation strategies on program implementation and youth's cardiovascular disease risk. hsrc is a texas a\&m agrilife extension initiative that supports the delivery of school-based physical activity and nutrition programs. elementary schools in north and east texas (n=16) of similar socio-economic status will be randomized at baseline to receive either 3, 2, 1, or no strategies to support hsrc program implementation. all schools will participate in hsrc during the full school year. the investigators hypothesize that one strategy will result in significantly greater hsrc implementation and effectiveness than the other strategies tested.

Eligibility criteria:
school inclusion criteria: * located in north and east texas * public elementary school student inclusion criteria" * at least 10 years old by september 1, 2023 (2024 for the 2024-2025 school year) * enrolled in the 5th or 6th grade * able to read, speak, and write in english exclusion criteria: * any motor or cognitive impairments or other health conditions that would prevent them from completing a physical assessment